Ascletis Pharma (OTCMKTS:ASCLF) Stock Price Down 16.5% – What’s Next?

Ascletis Pharma Inc. (OTCMKTS:ASCLF – Get Free Report)’s share price fell 16.5% during trading on Monday . The company traded as low as $0.18 and last traded at $0.18. 3,000 shares changed hands during trading, a decline of 69% from the average session volume of 9,560 shares. The stock had previously closed at $0.21. Ascletis [...]

featured-image

Ascletis Pharma Inc. ( OTCMKTS:ASCLF – Get Free Report )’s share price fell 16.5% during trading on Monday .

The company traded as low as $0.18 and last traded at $0.18.



3,000 shares changed hands during trading, a decline of 69% from the average session volume of 9,560 shares. The stock had previously closed at $0.21.

Ascletis Pharma Stock Performance The business has a 50 day moving average of $0.17 and a 200 day moving average of $0.16.

About Ascletis Pharma ( Get Free Report ) Ascletis Pharma Inc, a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.

Recommended Stories Five stocks we like better than Ascletis Pharma Stock Splits, Do They Really Impact Investors? Is Monolithic Power Systems a Screaming Buy After Near 40% Drop? Stock Ratings and Recommendations: Understanding Analyst Ratings Applied Materials Market Capitulates: Now is the Time to Buy What are earnings reports? 3 Ultra-High Dividend Yield Stocks for the New Year Receive News & Ratings for Ascletis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascletis Pharma and related companies with MarketBeat.com's FREE daily email newsletter ..